| Name | Title | Contact Details |
|---|
Toda la regulación del sector energético colombiano compilada y actulizada en una sola plataforma
People always ask, what does strategic communications mean? For us, it means finding interesting, smart, and inventive ways to get information to the right people. It means streamlining programs that are cumbersome, messy, and confusing and making them easy to use. It means identifying dated layout and design and creating content that is stunning and engaging. Based in Natick, MA, Strategic Communications, Inc. (StratComm) has served the marketing, communications, training, and project management needs of nationwide Fortune 500 companies, many federal agencies, and all branches of the Armed Forces for over 45 years. Our team works with a variety of clients and delivers an array of services. We create high-quality publications, both print and electronic, and training platforms for leading corporations and organizations such as IBM, VMware, the United States Navy and Air Force, the U.S. Department of State, Veterans Affairs, the U.S. Treasury, and many other important agencies and organizations. We also manage large programs for the federal government utilizing emerging technologies. Two examples are online training and testing programs for U.S. Embassies worldwide and program management for the Social Security Administration. Many high profile clients contract with StratComm to update the design and content of their websites, brochures, annual reports, and web apps. Our team is constantly seeking newer technologies and developing efficiencies to better serve our clients. Within our headquarters, we house a core team of dedicated professionals who administer our programs. Together, we manage varied projects and communications challenges for both large and small clients. Strategically, of course.
During its 20-plus-year history, MVB Bank has grown from a community bank with 35 employees to a forward-thinking, NASDAQ-listed, Russell 2000® company with more than 400 Team Members living in more than 25 different states. Headquartered in Fairmont, West Virginia, MVB Bank and the Banks subsidiaries, the MVB Community Development Corp., Chartwell Compliance, Paladin and Trabian, provide financial services to individuals and corporate clients in the Mid-Atlantic region and beyond. MVB Financial Corp., the holding company of MVB Bank, is publicly traded on The Nasdaq Capital Market under the ticker "MVBF."
The Volkswagen Group with its headquarters in Wolfsburg is one of the worlds leading automobile manufacturers and the largest carmaker in Europe. The Group is made up of ten brands from seven European countries: Volkswagen, Volkswagen Nutzfahrzeuge, ŠKODA, SEAT, CUPRA, Audi, Lamborghini, Bentley, Porsche and Ducati. Our group sells vehicles in 153 countries and operates 114 production plants worldwide. Each working day, around 675,000 employees worldwide produce cars, are involved in vehicle-related services or work in the other fields of business. Our goal is to make mobility sustainable for us and for future generations. Our promise: With electric drive, digital networking and autonomous driving, we make the automobile clean, quiet, intelligent and safe. At the same time, our core product becomes even more emotional and offers a completely new driving experience. It is also becoming part of the solution when it comes to climate and environmental protection. In this way, the car can continue to be a cornerstone of contemporary, individual and affordable mobility in the future. #Shapingmobility Imprint & Legal: http://vw.de/legal-notice DAT: http://vw.de/dat
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.